U.S. Infrastructure Stock News

NasdaqGM:FRPT
NasdaqGM:FRPTFood

Freshpet (FRPT) Is Up 12.4% After Raising 2026 Sales Outlook And Margins Improving - Has The Bull Case Changed?

In early August 2026, Freshpet, Inc. reported second-quarter sales of US$305.59 million and net income of US$19.49 million, alongside meaningfully higher year-to-date profitability and earnings per share compared with the prior year. The company credited its strongest growth rate in over a year and highest adjusted gross margin since early 2020 to a mix shift toward loyal “MVP” households, rising buying rates, operational gains such as new bag technology, and reinforced this momentum by...
NasdaqCM:NAGE
NasdaqCM:NAGEPersonal Products

Niagen Bioscience (NAGE) Gains Fresh Momentum, Is The Stock Still Cheap?

Niagen Bioscience (NAGE) has moved back into the spotlight after two recent developments. A peer reviewed analysis highlighted Niagen supplementation’s impact on muscle epigenetic age acceleration, while Tru Niagen’s launch on Walmart.com expands its healthy aging reach. See our latest analysis for Niagen Bioscience. Recent announcements around Niagen Bioscience, including the peer reviewed muscle aging study and Tru Niagen’s Walmart.com debut, come after a challenging share price stretch...
NYSE:RGA
NYSE:RGAInsurance

What Reinsurance Group of America (RGA)'s Dividend Hike and Record Quarter Means For Shareholders

In early August 2026, Reinsurance Group of America reported second-quarter revenue of US$6,637 million and net income of US$462 million, both higher than a year earlier, alongside a 5.4% increase in its regular quarterly dividend to US$0.98 per share and continued execution of its share repurchase program. The combination of record operating results, stronger investment income, higher dividends, and ongoing buybacks highlights how RGA is using its balance sheet to enhance shareholder...
NasdaqGS:SPSC
NasdaqGS:SPSCSoftware

The Bull Case For SPS Commerce (SPSC) Could Change Following Mixed 2026 Outlook And Major Buyback - Learn Why

SPS Commerce, Inc. recently reported past second-quarter 2026 results, with sales rising to US$197.82 million while net income and diluted EPS from continuing operations fell to US$6.86 million and US$0.19, respectively, and also updated guidance calling for full-year 2026 revenue of US$788.4 million to US$793.4 million. Alongside these results, the company completed a US$113.64 million buyback equal to 4.93% of shares, signaling a meaningful capital return alongside expectations for revenue...
NYSE:TPR
NYSE:TPRLuxury

Tapestry (TPR) Looks Fairly Valued Following Its Future Now AI Summit

Tapestry (TPR) is back in focus after its second annual Future Now AI Summit, where the company highlighted how artificial intelligence is being used across consumer insights, store associate training, and enterprise decision intelligence. See our latest analysis for Tapestry. The Future Now AI Summit comes at a time of strong momentum in Tapestry’s stock, with a 30 day share price return of 15.86% and a 1 year total shareholder return of 50.75%. Over 3 years, the total shareholder return is...
NasdaqGS:KRYS
NasdaqGS:KRYSBiotechs

Did Stronger Q2 2026 Profitability Just Shift Krystal Biotech's (KRYS) Investment Narrative?

In August 2026, Krystal Biotech reported second-quarter 2026 results showing net income of US$54.77 million, up from US$38.33 million a year earlier, with basic earnings per share from continuing operations rising to US$1.85 and diluted earnings per share to US$1.79. Over the first six months of 2026, net income reached US$110.70 million and basic earnings per share from continuing operations climbed to US$3.76, highlighting a meaningful increase in profitability compared with the prior-year...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

Rhythm Pharmaceuticals (RYTM) Reports Promising RM 718 Data, Is The Upside Already Priced In?

RM-718 trial data puts Rhythm Pharmaceuticals (RYTM) pipeline in focus Rhythm Pharmaceuticals (RYTM) has drawn fresh investor attention after releasing preliminary Phase 2 data for RM-718 in acquired hypothalamic obesity, showing double digit mean BMI reductions and a generally well tolerated safety profile. See our latest analysis for Rhythm Pharmaceuticals. The RM-718 update has arrived alongside a sharp pickup in Rhythm Pharmaceuticals' share price momentum, with a 7-day share price return...
NYSE:AVTR
NYSE:AVTRLife Sciences

Avantor (AVTR) Lifts Guidance As Growth Returns But Is The Rally Fully Valued

Why Avantor Raised Full Year Guidance After Q2 Results Avantor (AVTR) raised its full year guidance after returning to organic growth in its distribution business, with the VWR segment showing earlier than expected improvement and the Revival program delivering measurable operational progress. The updated outlook follows second quarter 2026 earnings, where Avantor reported sales of US$1,692.3 million and net income of US$38.1 million, alongside modestly higher first half sales and lower net...
NYSE:SE
NYSE:SEMultiline Retail

Is Sea (SE) Trading Volatility Hinting At A Deeper Shift In Its Growth-Versus-Profits Playbook?

Sea Limited has moved back into focus this week as investors react to recent trading volatility and look ahead to its 11 August 2026 earnings release, with consensus pointing to year-over-year gains in both earnings per share and revenue across e-commerce and digital entertainment. Behind the headlines, the key tension is between upbeat growth expectations and mounting concern that heavier spending and higher credit loss provisions could weigh on profitability. Next, we’ll examine how this...
NYSE:ALL
NYSE:ALLInsurance

3 Stocks Berkshire’s Q2 Shift Could Lift Or Leave Exposed

Berkshire Hathaway has quietly flipped the script in Q2 2026, shifting from record cash reserves to heavier investing and buybacks, and that ripple is now reaching individual stocks. This change in behaviour can open up pockets of opportunity and pockets of risk for investors who pay attention. This article walks through three stocks exposed to the same forces, two potential beneficiaries and one possible loser, to help you decide where to lean in and where to be cautious. Allstate...
NYSE:MO
NYSE:MOTobacco

Is Altria Group (MO) Cheap Following Mixed Q2 Earnings And Tighter 2026 Guidance?

Altria Group (MO) moved back into focus after its late July Q2 2026 earnings release, which combined a revenue beat with an earnings miss and a tighter full year adjusted EPS outlook. See our latest analysis for Altria Group. The mixed Q2 2026 earnings picture and ongoing share buybacks appear to be key drivers behind Altria Group's recent moves, with the share price at US$68.35 after a 19.26% year to date share price return and a 5 year total shareholder return of 106.98%. This suggests...
NasdaqGS:TLRY
NasdaqGS:TLRYPharmaceuticals

Tilray Brands (TLRY) Could Be 55% Undervalued Following Its New Mollo Lite Launch

Tilray Brands (TLRY) just rolled out Mollo Lite Blackberry Lemon Seltzers as its first light THC beverage multipack in Canada, putting fresh attention on how the stock reflects its cannabis beverage platform. See our latest analysis for Tilray Brands. The new Mollo Lite launch lands after a mixed run for Tilray Brands, with a 1-day share price return of 2.93% to US$4.57 and a 30-day share price return of 4.10%, but a year-to-date share price decline of 52.98% and a 5-year total shareholder...
NYSE:CNMD
NYSE:CNMDMedical Equipment

CONMED (CNMD) Lifts Sales Outlook, Is The Stock 24% Overvalued?

Earnings and Guidance Update Put CONMED Stock in Focus CONMED (CNMD) drew fresh attention after reporting second quarter 2026 results, with net income and earnings per share higher than a year earlier and a modestly raised full year net sales outlook. See our latest analysis for CONMED. The latest earnings and modest guidance lift have come alongside a sharp shift in sentiment, with CONMED’s share price up 46.23% over the past month. However, the 1 year total shareholder return is still down...
NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

LivaNova (LIVN) Rebounds On Earnings As The Bull Case Points To More Upside

What LivaNova’s latest earnings mean for the stock now LivaNova (NasdaqGS:LIVN) released second quarter 2026 results that showed higher sales and a shift from last year’s loss to net income, which quickly put the stock back on many investors’ radars. See our latest analysis for LivaNova. LivaNova’s strong second quarter has landed on top of a share price that is now US$76.22, with a 1 year to date share price return of 25.69% and a 1 year total shareholder return of 56.06%, suggesting...
NYSE:BKE
NYSE:BKESpecialty Retail

Buckle (BKE) Could Be 2% Undervalued On Improved Sales Momentum

Buckle (BKE) shares are in focus after the retailer reported higher comparable store net sales and total net sales across the latest 4-week, second-quarter, and year-to-date periods. See our latest analysis for Buckle. The trading update appears to have shifted sentiment around Buckle, with the share price up 10.81% over the past month but still down 14.70% year to date on a share price return basis. The 5 year total shareholder return of 71.46% shows the longer term picture. If Buckle’s...
NYSE:TROX
NYSE:TROXChemicals

Tronox (TROX) Widens Losses Yet Maintains Dividend: What Does This Say About Capital Discipline?

In the second quarter of 2026, Tronox Holdings plc reported sales of US$868 million, up from US$731 million a year earlier, while its net loss widened to US$171 million and the Board maintained a US$0.05 quarterly dividend. The company’s guidance for a mid-single-digit moderation in third-quarter production volumes and the appointment of audit veteran Keith Schwarz to the Board highlight a focus on managing seasonal demand patterns while reinforcing financial oversight amid ongoing...
NasdaqGS:KLIC
NasdaqGS:KLICSemiconductor

Kulicke And Soffa Industries (KLIC) Lifts Guidance, Is The Stock Fully Valued?

Kulicke and Soffa Industries (KLIC) stock is back in focus after the company reported strong third quarter results, issued higher revenue and earnings guidance, and confirmed progress on capacity expansion in key advanced packaging areas. See our latest analysis for Kulicke and Soffa Industries. Against this backdrop, Kulicke and Soffa Industries’ recent earnings beat and higher guidance have come after a sharp reset. The 30 day share price return is 12.4% and the 90 day share price return is...
NasdaqGS:CME
NasdaqGS:CMECapital Markets

How CME’s Nano Futures Push and Dividend Move At CME Group (CME) Has Changed Its Investment Story

CME Group recently declared a third-quarter dividend of US$1.30 per share, payable on 25 September 2026 to shareholders of record on 9 September 2026, and has been expanding its derivatives lineup with launches such as E-nano equity index futures and new sports-related benchmarks through its partnership with FutureSports LLC. Together with growing adoption of smaller-sized contracts like Spot-Quoted futures and record trading activity in key currency products, these moves highlight CME...
NYSE:BIO
NYSE:BIOLife Sciences

Bio Rad Laboratories (BIO) Stock Looks Priced Above Fair Value

Bio-Rad Laboratories stock has rebounded in the short term, yet the current price around US$352 still screens as expensive relative to its intrinsic value estimate and market multiples. After a 5 year period where the share price fell 54.7%, the recent strength sits against valuation checks that point to a premium rather than a clear bargain. Over the last 5 years, Bio-Rad Laboratories is down 54.7%, which suggests long term holders have taken a significant hit even though the recent share...
NasdaqGS:NMRK
NasdaqGS:NMRKReal Estate

3 US Real Estate Stocks Investors Are Watching Before The Next Fed Decision

With the June 2026 CPI print landing just weeks before a key Federal Reserve meeting, interest rate expectations are again front and center for anyone watching US real estate stocks. Rate sensitive property companies can see their borrowing costs and valuations shift quickly when inflation surprises. This article breaks down how that backdrop connects to three stocks from a US Rate Sensitive Real Estate screener and why their reactions could matter for your portfolio. The three stocks below...
NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher Scientific (TMO) Showcases Diagnostics Momentum, Is The Valuation Upside Already Priced In?

Thermo Fisher Scientific event puts specialty diagnostics in focus Thermo Fisher Scientific (TMO) has put its specialty diagnostics business in the spotlight after showcasing new products and recent U.S. Food and Drug Administration clearances at the ADLM conference in Anaheim in late July 2026. The event highlighted the EXENT Solution for multiple myeloma monitoring and the EliA CTD 13 Screen for autoimmune disease testing, along with software and quality control tools designed to support...
NYSE:STT
NYSE:STTCapital Markets

The Bull Case For State Street (STT) Could Change Following New US$500 Million Perpetual Preferred Issuance

In early August 2026, State Street Corporation amended its Articles of Organization in Massachusetts to codify the terms of its new Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series L, including its US$100,000 per share liquidation preference and placement alongside other preferred series. This legal update followed the completion of a US$500 million offering of perpetual, callable, non-cumulative preferred depositary shares, highlighting an ongoing reshaping of State...
NasdaqGS:VRNS
NasdaqGS:VRNSSoftware

Varonis (VRNS) Is Up 8.9% After Launching AI Agent Access Controls And Raising 2026 Outlook

In early August 2026, Varonis Systems, Inc. launched Agent Intent-Based Access Control within its Atlas platform, adding safeguards that monitor AI agents’ reasoning, tool use, and data access, while also reporting second-quarter revenue of US$180.02 million and updated guidance for continued double-digit revenue growth in 2026. This combination of advanced controls for AI agent behavior and a reinforced growth outlook highlights how Varonis is aligning its data security platform with...
NYSE:WOR
NYSE:WORMachinery

Worthington Enterprises (WOR) Draws Attention On Value, Is It Still 11% Below Fair Value?

Worthington Enterprises stock snapshot after recent trading move Worthington Enterprises (WOR) has drawn investor attention after a recent trading move, with the stock last closing at $58.42. That price comes alongside a value score of 5 and an intrinsic discount of 36.9%. See our latest analysis for Worthington Enterprises. Recent trading fits into a broader picture for Worthington Enterprises, with a 30 day share price return of 10.69% and a year to date share price return of 12.43%. This...